Construction and Validation of New Nomograms to Predict Risk and Prognostic Factors of Breast Cancer Bone Metastasis in Asian Females: A Population-Based Retrospective Study

BackgroundMetastatic breast cancer (MBC) is a highly heterogeneous disease and bone is one of the most common metastatic sites. This retrospective study was conducted to investigate the clinical features, prognostic factors and benefits of surgery of breast cancer patients with initial bone metastases.MethodsFrom 2010 to 2015, 6,860 breast cancer patients diagnosed with initial bone metastasis were analyzed from Surveillance, Epidemiology, and End Results (SEER) database. Univariate and Multivariable analysis were used to identify prognostic factors. A nomogram was performed based on the factors selected from cox regression result. Survival curves were plotted according to different subtypes, metastatic burdens and risk groups differentiated by nomogram.ResultsHormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) positive patients showed the best outcome compared to other subtypes. Patients of younger age (<60 years old), white race, lower grade, lower T stage (<=T2), not combining visceral metastasis tended to have better outcome. About 37% (2,249) patients received surgery of primary tumor. Patients of all subtypes could benefit from surgery. Patients of bone-only metastases (BOM), bone and liver metastases, bone and lung metastases also showed superior survival time if surgery was performed. However, patients of bone and brain metastasis could not benefit from surgery (p = 0.05). The C-index of nomogram was 0.66. Cutoff values of nomogram point were identified as 87 and 157 points, which divided all patients into low-, intermediate- and high-risk groups. Patients of all groups showed better overall survival when receiving surgery.ConclusionOur study has provided population-based prognostic analysis in patients with initial bone metastatic breast cancer and constructed a predicting nomogram with good accuracy. The finding of potential benefit of surgery to overall survival will cast some lights on the treatment tactics of this group of patients.

Download Full-text

Prognosis of breast cancer patients with initial bone metastasis: A population-based study.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.e13081 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. e13081-e13081

Author(s):

Deyue LIU ◽

Jiayi Wu ◽

Li Zhu

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Prognostic Factors ◽

Metastatic Breast Cancer ◽

Bone Metastasis ◽

Cancer Patients ◽

Risk Group ◽

Metastatic Breast ◽

Population Based ◽

Breast Cancer Patients

e13081 Background: Metastatic breast cancer (MBC) is a highly heterogeneous disease and bone is one of the most common metastatic sites. This retrospective study was conducted to investigate the clinical features, prognostic factors and benefits of surgery of breast cancer patients with initial bone metastases. Methods: From 2010 to 2015, 6860 breast cancer patients diagnosed with initial bone metastasis were analysed from Surveillance, Epidemiology, and End Results (SEER) database. Univariate and Multivariable analysis were used to identify prognostic factors. A nomogram was performed based on the factors selected from cox regression result. Survival curves were plotted according to different subtypes, metastatic burdens and risk group differentiated by nomogram. Results: Hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) positive patients showed the best outcome compared to other subtypes. Patients of younger age ( < 60 years old), white race, lower grade, lower T stage ( < = T2), not combining organ metastasistend to have better outcome. About 37% (2249) patients received surgery of primary tumor. Patients of all subtypes can benefit from surgery. Patients of bone-only metastases (BOM), bone and liver metastases, bone and lung metastases also showed superior survival time if surgery is performed. While patients of bone and brain patients cannot benefit from surgery (p = 0.05). The C-index of nomogram is 0.68. A cutoff value of nomogram point was identified by ROC curve as 93 points, which divided all patients into low-risk group and high-risk group. Patients of both groups showed better overall survival when receiving surgery. Conclusions: Our study has provided population-based nomogram in patients with initial bone metastatic breast cancer. The finding of potential benefit of surgery to overall survival will cast some light on the treatment tactics of this group of patients.

Download Full-text

Risk factors and prognostic factors for inflammatory breast cancer with bone metastasis: A population-based study

10.21203/rs.3.rs-43528/v1 ◽

2020 ◽

Author(s):

Fang Shao

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Prognostic Factors ◽

Bone Metastasis ◽

Liver Metastases ◽

Inflammatory Breast Cancer ◽

Population Based ◽

Cancer Specific Survival ◽

Rare Type ◽

Cox Proportional Hazard

Abstract Background: Inflammatory breast cancer (IBC) is a rare type of breast cancer with poor prognosis. IBC patients with bone metastasis (BM) often suffer from many complications. This study was to identify risk factors with strong capability of predicting high BM risk for IBC patients and find prognostic factors of IBC patientsMethods: The Surveillance, Epidemiology and End Results (SEER) database was used to collect the clinicopathological and survival information of IBC patients. 966 IBC patients diagnosed between 2010 and 2015 were to study the risk factors for developing BM by using Multivariable logistic regression. 194 and 176 patients were to analyze independent prognostic factors for overall survival (OS) and cancer specific survival (CSS) of IBC patients with BM by performing Cox proportional hazard model.Results: Of the 966 IBC patients, 194 (20.1%) patients were with BM. IBC patients of unmarried, double breast tumor, N1 stage, N3 stage, and liver metastases had higher risk of BM, while those of uninsured status and triple negative breast cancer (TNBC) were less likely to have BM. The survival analysis showed that TNBC subtype and liver metastases were independently significantly associated with poorer OS and CSS of BM patients, while chemotherapy could serve as an independent prognostic factor for better OS and CSS of BM patients.Conclusions: The risk factors for developing BM could provide potential guidelines for screening BM in IBC patients. The independent prognostic factors for survival outcome of IBC patients with BM could help doctors precisely treat those patients.

Download Full-text

Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0028-1088610 ◽

2008 ◽

Vol 68 (S 01) ◽

Author(s):

C Schem ◽

DO Bauerschlag ◽

J Weimer ◽

M Zhang ◽

W Jonat ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastasis ◽

Breast Cancer Bone Metastasis ◽

Cox2 Expression

Download Full-text

Osteoblast-Derived PTHRP and Breast Cancer Bone Metastasis

10.21236/ada625302 ◽

2004 ◽

Author(s):

Andrew Karaplis

Keyword(s):

Breast Cancer ◽

Bone Metastasis ◽

Breast Cancer Bone Metastasis

Download Full-text

Biological and Toxicological Evaluation of N-(4methyl-phenyl)-4-methylphthalimide on Bone Cancer in Mice

Anti-Cancer Agents in Medicinal Chemistry ◽

10.2174/1871520619666190207130732 ◽

2019 ◽

Vol 19 (5) ◽

pp. 667-676

Author(s):

José R. Santin ◽

Gislaine F. da Silva ◽

Maria V.D. Pastor ◽

Milena F. Broering ◽

Roberta Nunes ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastasis ◽

In Silico ◽

Bone Matrix ◽

Micronucleus Assay ◽

Repeated Treatment ◽

Toxicological Evaluation ◽

Toxicological Analysis ◽

Breast Cancer Bone Metastasis

Background: It was recently demonstrated that the phthalimide N-(4-methyl-phenyl)-4- methylphthalimide (MPMPH-1) has important effects against acute and chronic pain in mice, with a mechanism of action correlated to adenylyl cyclase inhibition. Furthermore, it was also demonstrated that phthalimide derivatives presented antiproliferative and anti-tumor effects. Considering the literature data, the present study evaluated the effects of MPMPH-1 on breast cancer bone metastasis and correlated painful symptom, and provided additional toxicological information about the compound and its possible metabolites. Methods: In silico toxicological analysis was supported by in vitro and in vivo experiments to demonstrate the anti-tumor and anti-hypersensitivity effects of the compound. Results: The data obtained with the in silico toxicological analysis demonstrated that MPMPH-1 has mutagenic potential, with a low to moderate level of confidence. The mutagenicity potential was in vivo confirmed by micronucleus assay. MPMPH-1 treatments in the breast cancer bone metastasis model were able to prevent the osteoclastic resorption of bone matrix. Regarding cartilage, degradation was considerably reduced within the zoledronic acid group, while in MPMPH-1, chondrocyte multiplication was observed in random areas, suggesting bone regeneration. Additionally, the repeated treatment of mice with MPMPH-1 (10 mg/kg, i.p.), once a day for up to 36 days, significantly reduces the hypersensitivity in animals with breast cancer bone metastasis. Conclusion: Together, the data herein obtained show that MPMPH-1 is relatively safe, and significantly control the cancer growth, allied to the reduction in bone reabsorption and stimulation of bone and cartilage regeneration. MPMPH-1 effects may be linked, at least in part, to the ability of the compound to interfere with adenylylcyclase pathway activation.

Download Full-text